Epidermal growth factor receptor, c-kit, and her2/neu immunostaining in advanced or recurrent thymic epithelial neoplasms staged according to the 2004 world health organization in patients treated with octreotide and prednisone: an eastern cooperative oncology group study Academic Article uri icon


MeSH Major

  • Antineoplastic Agents, Hormonal
  • Neoplasms, Glandular and Epithelial
  • Octreotide
  • Prednisone
  • Proto-Oncogene Proteins c-kit
  • Receptor, Epidermal Growth Factor
  • Receptor, ErbB-2
  • Thymus Neoplasms


  • High EGFR immunoreactivity is seen in more aggressive thymic neoplasms as classified according to the 2004 WHO, but regardless of classification, the presence of EGFR in tumor cells (1+, 2+, and 3+) is associated with improved performance free survival (PFS) and a trend for better OS. In contrast, the absence of C-kit immunoreactivity was associated with improved PFS. These data suggest that EGFR and C-kit may be prognostic, and further studies of these markers in subcategories of thymic malignancies is warranted.

publication date

  • June 2010



  • Academic Article



  • eng

PubMed Central ID

  • PMC3061392

Digital Object Identifier (DOI)

  • 10.1097/JTO.0b013e3181d86a30

PubMed ID

  • 20421818

Additional Document Info

start page

  • 885

end page

  • 92


  • 5


  • 6